Compass, Inc. announced it will report Q2 2026 results on August 4, 2026. The filing also includes a synthetic earnings context showing a Q1 2026 EPS miss of -88.4% ($0.03 actual vs $0.26 consensus), which is a strong miss. The stock has historically underperformed following prior reports on this ticker, with a -7.88% average T+20 return and a 25% win rate, suggesting the market has been skeptical of bullish or neutral reads on this name. The cross-filing context shows no active activist or offering filings, so the amplifier verdicts for those combos are not triggered here. The standalone earnings miss is the primary driver, and given the magnitude of the miss and the historical underperformance, the impact is bearish but tempered by the fact that this is a forward-looking announcement of an upcoming earnings date, not the actual Q2 results. The actual Q1 miss is from a synthetic context and may not be the current period's focus, but it sets a negative tone. The filing is a routine earnings date announcement, but the embedded miss data makes it notable. The historical calibration shows that scores of 7+ on this ticker have performed poorly (avg T+20 -17.64% for the last score=7 call), so I will bias the impactScore downward to avoid over-scoring. The sentiment is bearish due to the strong EPS miss, but the impact is moderate because the filing is primarily an announcement of future results, not the release of those results. The confidence is medium because the earnings context is synthetic and may not reflect the actual Q2 2026 results being announced. The key facts are the Q2 2026 earnings date (August 4) and the Q1 2026 EPS miss. The actionable insight is to watch for the Q2 2026 results on August 4, as the Q1 miss and historical underperformance suggest downside risk. The risks include further earnings misses and negative market reaction. The related tickers are none explicitly named in the document. The time horizon is weeks (until the Q2 report). The drugNames array is empty as this is not a biotech filing. The crossFilingNarrative is null as no cross-filing context was provided beyond the calibration blocks. The data section reflects the synthetic earnings context: EPS actual $0.03 vs estimate $0.26, a miss of -88.4%, revenue actual not provided, revenue YoY growth not provided, guidance not provided, margins not provided, cash flow not provided. The earningsRating is strong_miss because the EPS miss is >10%. The whyItMoved is the EPS miss of -88.4% vs consensus. The impactScore is set to 6 (notable bearish event) rather than 7+ to avoid over-scoring given the historical underperformance and the fact that this is an earnings date announcement, not the full Q2 release. The sentiment is bearish, impactScore 6, confidence medium.
Price Chart
Executive Summary
Compass, Inc. announced it will report Q2 2026 results on August 4, 2026. The filing also includes a synthetic earnings context showing a Q1 2026 EPS miss of -88.4% ($0.03 actual vs $0.26 consensus), which is a strong miss. The stock has historically underperformed following prior reports on this ticker, with a -7.88% average T+20 return and a 25% win rate, suggesting the market has been skeptical of bullish or neutral reads on this name. The cross-filing context shows no active activist or offering filings, so the amplifier verdicts for those combos are not triggered here. The standalone earnings miss is the primary driver, and given the magnitude of the miss and the historical underperformance, the impact is bearish but tempered by the fact that this is a forward-looking announcement of an upcoming earnings date, not the actual Q2 results. The actual Q1 miss is from a synthetic context and may not be the current period's focus, but it sets a negative tone. The filing is a routine earnings date announcement, but the embedded miss data makes it notable. The historical calibration shows that scores of 7+ on this ticker have performed poorly (avg T+20 -17.64% for the last score=7 call), so I will bias the impactScore downward to avoid over-scoring. The sentiment is bearish due to the strong EPS miss, but the impact is moderate because the filing is primarily an announcement of future results, not the release of those results. The confidence is medium because the earnings context is synthetic and may not reflect the actual Q2 2026 results being announced. The key facts are the Q2 2026 earnings date (August 4) and the Q1 2026 EPS miss. The actionable insight is to watch for the Q2 2026 results on August 4, as the Q1 miss and historical underperformance suggest downside risk. The risks include further earnings misses and negative market reaction. The related tickers are none explicitly named in the document. The time horizon is weeks (until the Q2 report). The drugNames array is empty as this is not a biotech filing. The crossFilingNarrative is null as no cross-filing context was provided beyond the calibration blocks. The data section reflects the synthetic earnings context: EPS actual $0.03 vs estimate $0.26, a miss of -88.4%, revenue actual not provided, revenue YoY growth not provided, guidance not provided, margins not provided, cash flow not provided. The earningsRating is strong_miss because the EPS miss is >10%. The whyItMoved is the EPS miss of -88.4% vs consensus. The impactScore is set to 6 (notable bearish event) rather than 7+ to avoid over-scoring given the historical underperformance and the fact that this is an earnings date announcement, not the full Q2 release. The sentiment is bearish, impactScore 6, confidence medium.
Financial Impact
Not specified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302830274 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | Institutional Cluster | $11.75 $10.13 | ▼ −13.79% | ▼ −13.26% | $9.26 (−21.23%) |
Jul 21, 2026 10w ago | Press Release | $11.42 $12.30 | ▲ +7.71% | ▲ +5.14% | $9.26 (−18.96%) |
Jul 4, 2026 12w ago | Institutional Cluster | $12.99 $11.39 | ▼ −12.32% | ▼ −11.75% | $9.26 (−28.75%) |
May 6, 2026 21w ago | 144 | $8.74 $7.61 | ▼ −12.93% | ▼ −16.07% | $9.26 (+5.89%) |
May 5, 2026 21w ago | 8-K | $9.24 $7.61 | ▼ −17.64% | ▼ −20.42% | $9.26 (+0.16%) |
Apr 17, 2026 24w ago | 8-K | $8.14 $7.75 | ▼ −4.79% | ▼ −10.16% | $9.26 (+13.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access